{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T23:38:14Z","timestamp":1722728294393},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.cca.2013.12.039","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T14:31:34Z","timestamp":1388845894000},"page":"48-54","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma"],"prefix":"10.1016","volume":"430","author":[{"given":"Kengo","family":"Fujimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ebinuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Fukamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Ohwada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeharu","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meizi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Bujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2013.12.039_bb0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2013.12.039_bb0010","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2013.12.039_bb0015","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.039_bb0020","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients","volume":"96","author":"Salven","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cca.2013.12.039_bb0025","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/sj.leu.2402105","article-title":"Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma","volume":"15","author":"Niitsu","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2013.12.039_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2006.00702.x","article-title":"Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"77","author":"Goto","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cca.2013.12.039_bb0035","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-009-0586-4","article-title":"Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP","volume":"135","author":"Hara","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.039_bb0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2011.01649.x","article-title":"Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens","volume":"87","author":"Goto","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cca.2013.12.039_bb0045","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3109\/10428194.2012.660627","article-title":"Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone","volume":"53","author":"Goto","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cca.2013.12.039_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0609.2001.00334.x","article-title":"A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma","volume":"66","author":"Niitsu","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cca.2013.12.039_bb0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00432-004-0600-9","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index","volume":"131","author":"Goto","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.039_bb0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdn677","article-title":"Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy","volume":"20","author":"Ennishi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cca.2013.12.039_bb0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00277-011-1363-4","article-title":"Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens","volume":"91","author":"Goto","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cca.2013.12.039_bb0070","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1046\/j.1365-2141.2003.04176.x","article-title":"Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients","volume":"120","author":"Rigolin","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cca.2013.12.039_bb0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/10245330310001621323","article-title":"Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion","volume":"8","author":"Aref","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.cca.2013.12.039_bb0080","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1161\/01.ATV.19.11.2687","article-title":"Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions","volume":"19","author":"Kanaki","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cca.2013.12.039_bb0085","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1161\/01.CIR.0000014413.91312.EF","article-title":"Enhanced expression of the LDL receptor family member LR11 increases migration of smooth muscle cells in vitro","volume":"105","author":"Zhu","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2013.12.039_bb0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/01.RES.0000120862.79154.0F","article-title":"LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration","volume":"94","author":"Zhu","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.cca.2013.12.039_bb0095","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1373\/clinchem.2009.127027","article-title":"Development of an immunoassay for the quantification of soluble LR11, a circulating marker of atherosclerosis","volume":"55","author":"Matsuo","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2013.12.039_bb0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2012.10.047","article-title":"Increased circulating soluble LR11 in patients with acute coronary syndrome","volume":"415","author":"Ogita","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2013.12.039_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ajo.2012.01.035","article-title":"Enhanced circulating soluble LR11 in patients with diabetic retinopathy","volume":"154","author":"Takahashi","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cca.2013.12.039_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000315539","article-title":"Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease","volume":"30","author":"Ikeuchi","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.cca.2013.12.039_bb0115","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.cca.2012.06.025","article-title":"Circulating soluble LR11\/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias","volume":"413","author":"Sakai","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2013.12.039_bb0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bjh.12467","article-title":"LR11: a novel biomarker identified in follicular lymphoma","volume":"163","author":"Kawaguchi","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cca.2013.12.039_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2013.12.039_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/S0962935193000018","article-title":"Biological significance of soluble IL-2 receptor","volume":"2","author":"Caruso","year":"1993","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.cca.2013.12.039_bb0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ajcp\/92.2.186","article-title":"Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features","volume":"92","author":"Chilosi","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cca.2013.12.039_bb0150","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"Rubin","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.cca.2013.12.039_bb0155","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2013.12.039_bb0160","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R\u03b1 facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cca.2013.12.039_bb0165","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20051364","article-title":"Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members","volume":"395","author":"Hermey","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/j.cca.2013.12.039_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/med.10054","article-title":"Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer","volume":"24","author":"de Bock","year":"2004","journal-title":"Med Res Rev"},{"key":"10.1016\/j.cca.2013.12.039_bb0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: the molecular crystal ball","volume":"27","author":"Thun\u00f8","year":"2009","journal-title":"Dis Markers"},{"key":"10.1016\/j.cca.2013.12.039_bb0180","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/sj.leu.2403250","article-title":"CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review","volume":"18","author":"B\u00e9n\u00e9","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2013.12.039_bb0185","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/ATVBAHA.106.137091","article-title":"A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages","volume":"27","author":"Ohwaki","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cca.2013.12.039_bb0190","doi-asserted-by":"crossref","first-page":"11877","DOI":"10.1074\/jbc.M112.442491","article-title":"The soluble form of LR11 protein is a regulator of hypoxia-induced, urokinase-type plasminogen activator receptor (uPAR)-mediated adhesion of immature hematological cells","volume":"288","author":"Nishii","year":"2013","journal-title":"J Biol Chem"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898113005342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898113005342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:16:06Z","timestamp":1716390966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898113005342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":36,"alternative-id":["S0009898113005342"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2013.12.039","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}